Israeli Prime Minister Benjamin Netanyahu has suggested using blockchain technology as a way to bypass or mitigate the impact of possible financial sanctions. This approach could offer a more secure and transparent method for financial transactions, potentially reducing reliance on traditional banking systems vulnerable to sanctions. The proposal highlights growing interest in blockchain as a tool for financial resilience amid geopolitical tensions. Further developments and government actions will be watched closely to see if this idea moves toward implementation.
Regarding Israeli Prime Minister Benjamin Netanyahu's blockchain proposal, here is Pluang's market snapshot as of Oct 26, 2026 18:21 WIB: Of 50 major cryptocurrencies priced on Pluang, 26 rose and 23 fell today. Notable movers include COMP at Rp376.628 with a 1-day change of -9.80% and a Pluang order activity of 31% Sell / 69% Buy, EOS at Rp12.649 up 8.13%, and BAT at Rp2.625 down 6.24% with 84% Sell activity. The most notable figure is EOS's 8.13% gain.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
